189 related articles for article (PubMed ID: 27916010)
41. Ethical evaluation in health technology assessment reports: an eclectic approach.
Autti-Rämö I; Mäkelä M
Int J Technol Assess Health Care; 2007; 23(1):1-8. PubMed ID: 17234010
[TBL] [Abstract][Full Text] [Related]
42. OVERVIEW ON THE CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN THE HEALTHCARE SYSTEM IN HUNGARY.
Németh B; Csanádi M; Kaló Z
Int J Technol Assess Health Care; 2017 Jan; 33(3):333-338. PubMed ID: 28434433
[TBL] [Abstract][Full Text] [Related]
43. TOWARD INTEGRATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT: THE NEED FOR EVALUATIVE FRAMEWORKS.
van der Wilt GJ; Gerhardus A; Oortwijn W
Int J Technol Assess Health Care; 2017 Jan; 33(5):586-590. PubMed ID: 29256849
[TBL] [Abstract][Full Text] [Related]
44. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
Mittermayer R; Huić M; Mestrović J
Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
[TBL] [Abstract][Full Text] [Related]
45. INTRODUCTION OF INNOVATIVE MEDICAL DEVICES AT FRENCH UNIVERSITY HOSPITALS: AN OVERVIEW OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT INITIATIVES.
Martelli N; Billaux M; Borget I; Pineau J; Prognon P; van den Brink H
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):12-8. PubMed ID: 25991072
[TBL] [Abstract][Full Text] [Related]
46. How to introduce more (or better) ethical arguments in HTA?
Schokkaert E
Int J Technol Assess Health Care; 2015 Jan; 31(3):111-2. PubMed ID: 26044817
[TBL] [Abstract][Full Text] [Related]
47. EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE.
Goetghebeur MM; Wagner M; Samaha D; O'Neil W; Badgley D; Castro-Jaramillo H; Abrishami P; Sarria-Santamera A; Cleemput I; Tringali M
Int J Technol Assess Health Care; 2017 Jan; 33(4):504-520. PubMed ID: 29019295
[TBL] [Abstract][Full Text] [Related]
48. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
Rand LZ; Kesselheim AS
J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
[TBL] [Abstract][Full Text] [Related]
49. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
[TBL] [Abstract][Full Text] [Related]
50. Application of strengths, weaknesses, opportunities and threats analysis in the development of a health technology assessment program.
Gibis B; Artiles J; Corabian P; Meiesaar K; Koppel A; Jacobs P; Serrano P; Menon D
Health Policy; 2001 Oct; 58(1):27-35. PubMed ID: 11518600
[TBL] [Abstract][Full Text] [Related]
51. Regional HTA in Italy: promising or confusing?
Garattini L; van de Vooren K; Curto A
Health Policy; 2012 Dec; 108(2-3):203-6. PubMed ID: 23141760
[TBL] [Abstract][Full Text] [Related]
52. Integration of ethical considerations into HTA reports: an analysis of integration levels using a systematic review.
Legault GA; Gagnon H; Parent M; Bellemare CA; Béland JP; Kocsis-Bédard S; Bernier L; Dagenais P; Daniel CÉ; Patenaude J
Int J Technol Assess Health Care; 2021 Apr; 37(1):e61. PubMed ID: 33896427
[TBL] [Abstract][Full Text] [Related]
53. A situational and stakeholder analysis of health technology assessment in Zimbabwe.
Dzingirai B; Dambiko P; Matyanga C; Manyau P; Tagwireyi D; Postma MJ; Mafirakureva N; van Hulst M
Int J Technol Assess Health Care; 2024 Apr; 40(1):e27. PubMed ID: 38679461
[TBL] [Abstract][Full Text] [Related]
54. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
55. FRAMEWORK FOR USER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT AT THE LOCAL LEVEL: VIEWS OF HEALTH MANAGERS, USER REPRESENTATIVES, AND CLINICIANS.
Gagnon MP; Desmartis M; Gagnon J; St-Pierre M; Rhainds M; Coulombe M; Tantchou MD; Légaré F
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):68-77. PubMed ID: 25952585
[TBL] [Abstract][Full Text] [Related]
56. INTEGRATE-HTA: THE PERSPECTIVE OF EUnetHTA.
Lampe K; Schnell-Inderst P
Int J Technol Assess Health Care; 2017 Jan; 33(5):605-608. PubMed ID: 28874222
[TBL] [Abstract][Full Text] [Related]
57. Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening.
Potter BK; Avard D; Graham ID; Entwistle VA; Caulfield TA; Chakraborty P; Kennedy C; McGuire M; Griener GG; Montgomery M; Wells GA; Wilson BJ
Int J Technol Assess Health Care; 2008; 24(4):412-22. PubMed ID: 18828935
[TBL] [Abstract][Full Text] [Related]
58. The role of ethical analysis in conducting a health technology assessment of medical treatments for gender dysphoria.
Saarni SI; Uusitalo S; Autti-Rämö I
Int J Technol Assess Health Care; 2022 Nov; 38(1):e82. PubMed ID: 36373501
[TBL] [Abstract][Full Text] [Related]
59. Scientific Development of HTA-A Proposal by the Health Technology Assessment International Scientific Development and Capacity Building Committee.
van der Wilt GJ; Rüther A; Trowman R
Int J Technol Assess Health Care; 2019; 35(4):263-265. PubMed ID: 31355736
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
